好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Study of Yerba Mate (Ilex Paraguariensis) as a Neuroprotective Agent of Dopaminergic Neurons in an Animal Model of Parkinson's Disease
Movement Disorders
P5 - Poster Session 5 (5:30 PM-6:30 PM)
10-008

We propose to characterize the extract of YM and to evaluate if the consumption of YM provides a beneficial effect on the survival of dopaminergic neurons in parkinsonian mice.

The clinical signs of Parkinson's disease (PD) are a consequence of the degeneration of the dopaminergic neurons in the substantia nigra. Since the mechanisms that underlie this neuronal degeneration have not been fully clarified, currently there is no preventive therapy for PD. However, an inverse association was found between coffee intake or smoking and the occurrence of PD. Similarly, a case-control study conducted in Argentina in 2013 revealed that consumption of ‘mate’ also has an inverse association with the risk of developing PD. Mate is a drink widely consumed in several South American countries, made with yerba mate (YM), obtained from the plant Ilex paraguariensis.

The extract of YM was obtained by ‘cebada simulada’ and the main bioactive compounds caffeine, theobromine, chlorogenic acid and rutin were quantified by HPLC. Wild type mice were lesioned unilaterally with 6-OHDA in the striatum and treated and received water or ‘mate’ as their only source of fluid. During the treatment, locomotor activity was evaluated in open field (OF) session and the striatal tissue was processed by immunohistochemistry for TH to evaluate the degree of dopaminergic denervation.

The infusion of YM was well accepted by the animals. Mice that drink mate have a hyperlocomotor behavior in relation to control during OF session. The protocol of denervation obtained induces a lesion between 31 and 57%. Mice treated with YM have a density of striatal TH+ remaining fibers higher than the control mice.

These results could contribute to the development of novel therapeutic interventions, using YM in association with the frequently used antiparkinsonian drugs and to have thus a direct impact on the quality of life of patients.

Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Oscar S. Gershanik, MD (Hospital Frances) No disclosure on file
Emilia M. Gatto, MD, FAAN (INEBA) Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving as a Consultant for Bago Argentina. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bago. Dr. Gatto has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Gatto has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Janssen. Dr. Gatto has received research support from Roche. The institution of Dr. Gatto has received research support from CHDI.
No disclosure on file